Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

Palatin believes that its existing capital resources will be adequate to fund its currently planned operations, including completing analysis of results of the Company's Phase 2B clinical trial with bremelanotide for FSD, holding an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA), and commencing Phase 3 activities, through at least calendar year 2013.

CONFERENCE CALL / WEBCAST
Palatin will host a conference call and webcast on February 14, 2013 at 11:00 a.m. Eastern time to discuss the results of operations and an update on corporate developments in greater detail.  Individuals interested in listening to the conference call live can dial 1-888-539-3678 (domestic) or 1-719-325-2329 (international) pass code 4795478.  The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 4795478.  The webcast and telephone replay will be available through February 21, 2013.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.

Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of P
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 29, 2014 Global polyvinyl ... the world economic crisis during 2008-2009, especially in North ... recovered and currently is keeping to a growing trend. ... volume is utilized in the construction segment. In 2013, ... pipes, profiles, tubing, sheets and rigid film. Moreover, the ...
(Date:10/30/2014)... James Sherley says he has been working towards ASCTC ... his days as a principal investigator at the Fox Chase ... Sherley founded the ASCTC as a new Boston biotech start-up ... developed in Sherley’s research over the years since FCCC, first ... and more recently as a senior scientist at the now ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/27/2014)... North Carolina (PRWEB) October 27, 2014 ... invited earlier this month to sit down with Bryan Hamilton, ... from RPG Solutions to discuss talent in the Research Triangle ... topics that were highlighted at the roundtable include ... the Triangle, the significance of work/life balance and the unique ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... Family of, Tissue Dissection Tools, Which Have Been Used ... ... Calif., Oct. 28 PEAK Surgical, Inc., a,medical device company ... proprietary technology, has introduced two extensions to its,PEAK PlasmaBlade(TM) family ...
... Senomyx,s Discovery of a Promising New Flavor Ingredient Achieves ... Collaboration ... (Nasdaq: SNMX ), a leading company focused on using proprietary,technologies ... ingredient supply industries, announced today that it has,received a payment from ...
... to Advance P-552, DURHAM, N.C., Oct. 28 ... they have entered into an agreement to,co-develop Parion,s proprietary ... mouth associated with primary Sjogren,s syndrome., Under the ... P-552. Kainos will provide funding to help advance the,program ...
Cached Biology Technology:PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery 2PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery 3SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment 2Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment 3
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
(Date:10/29/2014)... potential of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen ... these into a human-readable text developed in manuscript within ... used to study the species distributions of ten Nearctic ... BOLD is originally designed to support the generation and ...
(Date:10/29/2014)... 2014 – Ghrelin is a hormone released by the ... is commonly viewed as a psychoactive substance that primarily ... caloric food. , This knowledge, combined with findings ... ghrelin has the potential to stimulate alcohol craving. , ... humans and found that, as they had anticipated, alcohol ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... found a critical piece in the evolutionary puzzle that ... ago. The team, from the School of Biomedical ... into more complex cells and found this crucial step ... thought. Team leader and ARC Federation Fellow ...
... The Translational Genomics Research Institute (TGen) today announced the ... the Van Andel Research Institute (VARI) that will maximize ... TGen expects the agreement to create a robust basic-science-to-translational ... for patient benefit. "We are ...
... are especially reactive to stress are more vulnerable to ... their peers. But a new longitudinal study suggests that ... well when they,re raised in supportive environments. The ... the University of California, San Francisco, and the University ...
Cached Biology News:An answer to another of life's big questions 2TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3High sensitivity to stress isn't always bad for children 2
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: